Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBIO NASDAQ:NEUP NYSE:NKGN NASDAQ:PALI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBIOMustang Bio$2.21-7.5%$1.44$0.89▼$24.00$10.46M2.161.61 million shs770,839 shsNEUPNeuphoria Therapeutics$7.46-1.3%$6.56$2.12▼$12.55$14.21M0.531,716 shs45,047 shsNKGNNKGen Biotech$0.26-7.1%$0.29$0.10▼$1.37$11.69M1.261.57 million shs64,430 shsPALIPalisade Bio$0.75+0.1%$0.72$0.60▼$4.89$3.60M1.36550,072 shs27,543 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBIOMustang Bio-7.53%-28.94%+99.10%+66.17%-89.08%NEUPNeuphoria Therapeutics-1.32%0.00%+11.34%+45.14%+745,999,900.00%NKGNNKGen Biotech-7.14%-13.48%-15.00%+103.92%-71.05%PALIPalisade Bio+0.13%-1.18%+23.11%+4.32%-83.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMBIOMustang Bio0.9229 of 5 stars0.05.00.00.02.20.00.6NEUPNeuphoria Therapeutics2.2318 of 5 stars3.50.00.00.03.80.00.6NKGNNKGen Biotech0.2647 of 5 stars0.03.00.00.00.02.50.0PALIPalisade Bio2.7075 of 5 stars3.54.00.00.01.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBIOMustang Bio 0.00N/AN/AN/ANEUPNeuphoria Therapeutics 3.00Buy$21.00181.50% UpsideNKGNNKGen Biotech 0.00N/AN/AN/APALIPalisade Bio 3.00Buy$12.001,497.87% UpsideCurrent Analyst Ratings BreakdownLatest PALI, NEUP, MBIO, and NKGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025PALIPalisade BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/ANEUPNeuphoria Therapeutics$10K1,402.48N/AN/A$15.85 per share0.47NKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/APALIPalisade BioN/AN/AN/AN/A$2.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)NEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)NKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/APALIPalisade Bio-$14.44M-$6.80N/AN/AN/AN/A-178.96%-127.35%8/11/2025 (Estimated)Latest PALI, NEUP, MBIO, and NKGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025PALIPalisade Bio-$0.48N/AN/AN/AN/AN/A5/20/2025Q3 2025NEUPNeuphoria Therapeutics-$0.47$6.55+$7.02$6.55N/A$15.00 million5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/A5/12/2025Q1 2025PALIPalisade Bio-$0.84-$0.47+$0.37-$0.47N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBIOMustang BioN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBIOMustang BioN/A1.341.34NEUPNeuphoria TherapeuticsN/A11.0111.01NKGNNKGen BiotechN/A0.020.02PALIPalisade BioN/A2.842.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBIOMustang Bio9.95%NEUPNeuphoria Therapeutics15.90%NKGNNKGen Biotech76.17%PALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipMBIOMustang Bio0.21%NEUPNeuphoria Therapeutics0.69%NKGNNKGen Biotech10.36%PALIPalisade Bio3.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBIOMustang Bio1004.38 million4.37 millionNot OptionableNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/ANKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionablePALIPalisade Bio104.80 million4.64 millionNot OptionablePALI, NEUP, MBIO, and NKGN HeadlinesRecent News About These CompaniesPalisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of ...July 11, 2025 | morningstar.comMPalisade Bio, Inc. Appoints Dr. Emil Chuang to Board of ... - NasdaqJuly 11, 2025 | nasdaq.comPalisade Bio appoints to its Board of DirectorsJuly 9, 2025 | msn.comPalisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of DirectorsJuly 9, 2025 | globenewswire.comPalisade Bio (NASDAQ:PALI) Shares Down 1.8% - What's Next?July 9, 2025 | americanbankingnews.comTranspire follows in Boehringer's footsteps by licensing PDE4 inhibitor for lung diseaseJune 3, 2025 | fiercebiotech.comFPalisade Bio Reports Improved Quarterly LossesJune 2, 2025 | tipranks.comPalisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and ...May 28, 2025 | manilatimes.netMPalisade Bio, Inc.: Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn ...May 28, 2025 | finanznachrichten.dePalisade Bio reports positive Phase 1 results for new drugMay 28, 2025 | investing.comPalisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and ...May 28, 2025 | morningstar.comMPalisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative ColitisMay 27, 2025 | globenewswire.comPalisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel DiseasesMay 6, 2025 | globenewswire.comPalisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease SummitMay 1, 2025 | globenewswire.comHyundai’s Next-Gen Hybrid System Offers 45% Boost In Fuel EfficiencyApril 21, 2025 | msn.comPalisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108April 9, 2025 | markets.businessinsider.comPalisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108April 9, 2025 | globenewswire.comMaxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)March 27, 2025 | markets.businessinsider.comPalisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trialMarch 17, 2025 | finance.yahoo.comPalisade Bio commences dosing in first UC patient cohort in study of PALI-2108March 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePALI, NEUP, MBIO, and NKGN Company DescriptionsMustang Bio NASDAQ:MBIO$2.21 -0.18 (-7.53%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$2.20 0.00 (-0.23%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Neuphoria Therapeutics NASDAQ:NEUP$7.46 -0.10 (-1.32%) As of 07/16/2025 03:59 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.NKGen Biotech NYSE:NKGN$0.26 -0.02 (-7.14%) As of 07/16/2025 03:33 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Palisade Bio NASDAQ:PALI$0.75 +0.00 (+0.13%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.74 -0.01 (-0.93%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
